SEC Form 4	
------------	--

 \Box

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

													5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title Other (specify						
(Last)(First)(Middle)3. Date36 ROBINSON ROAD04/12/2#13-01 CITY HOUSE					e of Earliest Transaction (Month/Day/Year) 2/2019									below)	,		below)	лосоп у	
(Street) SINGAPORE U0 068877					f Amendment, Date of Original Filed (Month/Day/Year)							6	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person						
(City)	(State)	(Zip)																
Table I - Non-Derivative S 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)				2A. Deemed Execution Date, if any		3. Transa Code (ction	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		A) or		5. Amount of Securities Beneficially		6. Ownership Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial			
					(Month/Day/Year)		r) 8) Code	v	Amount	(A) or (D) PI		Price	e	Owned Fo Reported Transactic (Instr. 3 ar	-	(I) (Instr. 4)		Ownership (Instr. 4)	
Common	Stock			04/12/2	2019			Α		3,636,3	364	Α	\$ <mark>2</mark> .	75 ⁽¹⁾	11,85	7,676	Γ) (2)(3)	
			Table II -			ecurities alls, warı									wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code	action (Instr.	Derivative I		6. Date Exercisa Expiration Date (Month/Day/Yea		e	Secu Deriv	7. Title and An Securities Und Derivative Sec (Instr. 3 and 4)		ng	8. Price of Derivative Security (Instr. 5)	9. Numbo derivativ Securitie Beneficia Owned Followin Reported	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisat		Expiration Date	Title	N	mount umber hares			Transact (Instr. 4)	ion(s))	
Warrant (Right to Buy)	\$2.9	04/12/2019		Α		3,636,364		(4)	(07/12/2020	Com Sto		,636,	364	(1)	3,636,	364	D ⁽²⁾⁽³⁾	
Warrant (Right to Buy)	\$2.9	04/12/2019		A		3,636,364		(4)		04/12/2024	Com Sto	ock 3	,636,	364	(1)	3,636,	364	D ⁽²⁾⁽³⁾	
	nd Address of the state of the	f Reporting Person [*] d.	r			1													
	INSON RO CITY HOU:		(Middle)															
(Street) SINGAI	PORE	U0	06887	7															
(City)		(State)	(Zip)																
	nd Address of Arun Kum	f Reporting Person [*] <u>1ar</u>																	
(Last) #30, 157 J.P. NAC	T MAIN GAR 3RD F	(First) PHASE	(Middle)															
(Street) BANGA	LORE	К7	56007	8															
(City)		(State)	(Zip)																
	nd Address of an Ghiath	f Reporting Person [*]																	
(Last)		(First)	(Middle)															

7TH CIRCLE, ZAHRAN STREET ZAHRAN PLAZA BLDG, 4TH FLOOR

(Street) AMMAN	M2	11844
(City)	(State)	(Zip)

Explanation of Responses:

1. The Common Stock together with the 15-month and 5-year Common Stock Warrants reported in Table II herein were acquired by BioLexis Pte Ltd ("BioLexis") in the Issuers combined public offering of the Common Stock and accompanying Warrants. The purchase price for the combined offering of the shares of Common Stock and the accompanying Warrants is \$2.75 per share.

2. These securities are held of record by BioLexis. Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.

3. By virtue of the relationships described above in Footnote 2, Kumar and Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

4. Immediately exercisable.

Remarks:

/s/ Faisal G. Sukhtian	<u>04/16/2019</u>
/s/ Arun Kumar Pillai	04/16/2019
/s/ Ghiath M. Sukhtian	<u>04/16/2019</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.